Genmab licenses HuMax-IL8 to Cormorant Pharmaceuticals
Human antibody will be evaluated for the treatment of selected cancers
Genmab, a Danish developer of human antibody therapeutics for the treatment of cancer, has granted an exclusive, worldwide licence to its HuMax-IL8 antibody to Cormorant Pharmaceuticals.
Under the terms of the agreement, Genmab will receive an upfront payment of an undisclosed amount and will be entitled to milestone payments and royalties on net sales.
Cormorant will evaluate HuMax-IL8 for treatment of selected cancers and will be responsible for all future costs of developing, manufacturing and marketing HuMax-IL8.
‘We are pleased to enter this licence agreement with Cormorant Pharmaceuticals who will work towards resuming the development of HuMax-IL8,’ said Jan van de Winkel, chief executive of Genmab.